Pivotal Phase III study shows Roche's Tecentriq helped people with early lung cancer live longer without their disease returningGlobeNewsWire • 03/22/21
Pivotal Phase III Study Shows Genentech's Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease ReturningBusiness Wire • 03/22/21
Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labsGlobeNewsWire • 03/17/21
Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutationsGlobeNewsWire • 03/16/21
New two-year data show Roche's Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)GlobeNewsWire • 03/16/21
New 2-Year Data Show Genentech's Evrysdi (risdiplam) Continues to Demonstrate Improvement or Maintenance of Motor Function in People Aged 2-25 With Type 2 or Type 3 Spinal Muscular Atrophy (SMA)Business Wire • 03/16/21
GenMark Shares Surge After Roche Announces $1.8 Billion Deal for Molecular Test MakerBarrons • 03/15/21
Roche Boosts Diagnostics Portfolio With $1.8B Bet On COVID-19 Test Manufacturer GenMarkBenzinga • 03/15/21
Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sampleGlobeNewsWire • 03/15/21
Roche's Tocilizumab, Gilead's Remdesivir Combo Fails To Improve Hospital Discharge Time in COVID-19 StudyBenzinga • 03/11/21
Roche's awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 SystemsGlobeNewsWire • 03/11/21
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumoniaGlobeNewsWire • 03/11/21
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 PneumoniaBusiness Wire • 03/11/21
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)PRNewsWire • 03/09/21